Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 1 5 versus METICORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 1 5 versus METICORTEN.
DEXONE 1.5 vs METICORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression and suppressing inflammation, immune response, and adrenal function.
1.5 mg orally once daily
5-60 mg orally once daily, depending on condition; for acute exacerbations, up to 250 mg IV every 4-6 hours.
None Documented
None Documented
Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
Following oral or IV administration, the terminal elimination half-life of total prednisolone (active form) is 2.1–3.5 hours in adults with normal hepatic function. In hepatic impairment, half-life may be prolonged (up to 6–8 hours), necessitating dose adjustment.
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Primarily renal: approximately 80% as inactive metabolites (conjugated and oxidized forms) and <5% as unchanged prednisolone. Biliary/fecal excretion accounts for about 10-15% of the dose.
Category C
Category C
Corticosteroid
Corticosteroid